摘要
Sodium-glucose cotransporter 2(SGLT2) inhibition induces glucosuria and decreases blood glucose levels in diabetic patients and lowers hypoglycemic risk. SGLT1 is expressed in the kidney and intestine; SGLT1 inhibition causes abdominal symptoms such as diarrhea and reduces incretin secretion. Therefore, SGLT2 selectivity is important. Ipragliflozin is highly selective for SGLT2. In type 2 diabetes mellitus(T2DM), urinaryglucose excretion increased to 90 g/24 h after 28 d of treatment with ipragliflozin 300 mg/d. Twelve weeks of ipragliflozin 50 mg/d vs placebo reduced glycated hemoglobin and body weight by 0.65% and 0.66 kg, respectively, in Western T2 DM patients, and by 1.3% and 1.89 kg, respectively, in Japanese patients. Ipragliflozin(highly selective SGLT2 inhibitor) improves glycemic control and reduces body weight and lowers hypoglycemic risk and abdominal symptoms. Ipragliflozin can be a novel anti-diabetic and antiobesity agent.
Sodium-glucose cotransporter 2 （SGLT2） inhibitioninduces glucosuria and decreases blood glucose levelsin diabetic patients and lowers hypoglycemic risk.SGLT1 is expressed in the kidney and intestine; SGLT1inhibition causes abdominal symptoms such as diarrheaand reduces incretin secretion. Therefore, SGLT2selectivity is important. Ipragliflozin is highly selectivefor SGLT2. In type 2 diabetes mellitus （T2DM）, urinaryglucose excretion increased to 90 g/24 h after 28 d oftreatment with ipragliflozin 300 mg/d. Twelve weeksof ipragliflozin 50 mg/d vs placebo reduced glycatedhemoglobin and body weight by 0.65% and 0.66kg, respectively, in Western T2DM patients, and by1.3% and 1.89 kg, respectively, in Japanese patients.Ipragliflozin （highly selective SGLT2 inhibitor） improvesglycemic control and reduces body weight andlowers hypoglycemic risk and abdominal symptoms.Ipragliflozin can be a novel anti-diabetic and antiobesityagent.
